Understanding the trends in international agreements on pricing and reimbursement for newly marketed medicines and their implications for access to medicines: a computational text analysis
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 손경복 | - |
dc.date.accessioned | 2023-08-16T07:43:22Z | - |
dc.date.available | 2023-08-16T07:43:22Z | - |
dc.date.issued | 2020-12 | - |
dc.identifier.issn | 1744-8603 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/erica/handle/2021.sw.erica/114161 | - |
dc.description.abstract | Background: Health systems are struggling with unprecedented drug spending and governments have devised various policy options to manage high-priced medicines. Meanwhile, some pricing and reimbursement processes are currently moving under the jurisdiction of international agreements. This study aims to understand trends in international agreements from the perspectives of pricing and reimbursement policies for newly marketed medicines. Methods: We proposed the framework to interpret the international agreements as code and applied computational text analysis to understand international agreements as data. In particular, we selected the AUSFTA, KORUS, and TPP to assess the progress and evolution in international agreements and investigate the existing relevant content on the pricing and reimbursement of newly marketed medicines. Results: Similar to the provisions for intellectual property, the scope of international agreements regarding pricing and reimbursement decisions are broadened and strengthened. Over time, the domain of transparency, re-naming procedural fairness, has changed significantly more than the remaining domains. Pharmaceutical companies will have more opportunities to advocate for their positions, to protect their interests in decision processes, to investigate the decisions on listings and setting the amounts of reimbursement, and to challenge these decisions. Conclusions: Recently signed international agreements favor companies over governments with underscoring procedural fairness and timely access. However, access to affordable medicines is the goal towards which international agreements should aim. In a similar vein, substantial fairness and the accountability of companies should be discussed when negotiating agreements or adopting international agreements through domestic legislation. © 2020, The Author(s). | - |
dc.format.extent | 12 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | BioMed Central | - |
dc.title | Understanding the trends in international agreements on pricing and reimbursement for newly marketed medicines and their implications for access to medicines: a computational text analysis | - |
dc.type | Article | - |
dc.publisher.location | 영국 | - |
dc.identifier.doi | 10.1186/s12992-020-00633-9 | - |
dc.identifier.scopusid | 2-s2.0-85092613952 | - |
dc.identifier.wosid | 000579329900001 | - |
dc.identifier.bibliographicCitation | Globalization and Health, v.16, no.1, pp 1 - 12 | - |
dc.citation.title | Globalization and Health | - |
dc.citation.volume | 16 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 1 | - |
dc.citation.endPage | 12 | - |
dc.type.docType | 정기학술지(Article(Perspective Article포함)) | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | ssci | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Public, Environmental & Occupational Health | - |
dc.relation.journalWebOfScienceCategory | Public, Environmental & Occupational Health | - |
dc.subject.keywordPlus | TRANS-PACIFIC PARTNERSHIP | - |
dc.subject.keywordPlus | MANAGED ENTRY AGREEMENTS | - |
dc.subject.keywordPlus | INTELLECTUAL PROPERTY | - |
dc.subject.keywordPlus | HEALTH | - |
dc.subject.keywordPlus | LEGISLATION | - |
dc.subject.keywordPlus | TECHNOLOGY | - |
dc.subject.keywordPlus | PRICES | - |
dc.subject.keywordPlus | ACCO | - |
dc.subject.keywordPlus | UNTABILITYUNCERTAINTY | - |
dc.subject.keywordPlus | LEGITIMACY | - |
dc.subject.keywordAuthor | Access to medicines | - |
dc.subject.keywordAuthor | International agreements | - |
dc.subject.keywordAuthor | Pricing and reimbursement | - |
dc.subject.keywordAuthor | Procedural fairness | - |
dc.identifier.url | https://www.scopus.com/record/display.uri?eid=2-s2.0-85092613952&origin=inward&txGid=c565c07434c378f2f602946c0402990a | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
55 Hanyangdeahak-ro, Sangnok-gu, Ansan, Gyeonggi-do, 15588, Korea+82-31-400-4269 sweetbrain@hanyang.ac.kr
COPYRIGHT © 2021 HANYANG UNIVERSITY. ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.